Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L7DL
|
||||
| Former ID |
DNC006533
|
||||
| Drug Name |
8-cyclohexyl-6-(4-tolyl)-2-phenyl-9H-purine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H24N4
|
||||
| Canonical SMILES |
CC1=CC=C(C=C1)C2=C3C(=NC(=N2)C4=CC=CC=C4)N=C(N3)C5CCCCC<br />5
|
||||
| InChI |
1S/C24H24N4/c1-16-12-14-17(15-13-16)20-21-24(27-22(25-20)18-8-4-2-5-9-18)28-23(26-21)19-10-6-3-7-11-19/h2,4-5,8-9,12-15,19H,3,6-7,10-11H2,1H3,(H,25,26,27,28)
|
||||
| InChIKey |
JOTMQRFWDYAWIE-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A1 receptor | Target Info | Inhibitor | [1] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Reactome | Adenosine P1 receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | J Med Chem. 2006 May 18;49(10):2861-7.2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.